Literature DB >> 17599812

Relative contribution of peripheral versus central opioid receptors to antinociception.

Dominika Labuz1, Shaaban A Mousa, Michael Schäfer, Christoph Stein, Halina Machelska.   

Abstract

Opioid effects are mediated by central and peripheral opioid receptors. Here we examine the relative contribution of each receptor population to antinociception elicited by systemically administered centrally penetrating opioids, and by loperamide (a peripherally restricted opioid). Nociception (abdominal writhes) was induced by intraperitoneally (i.p.) injected 0.6% acetic acid in mice. We analyzed opioid receptor expression in peritoneum by immunohistochemistry, antinociception after i.p. injected agonists at mu (morphine, loperamide)-, delta (SNC80)- and kappa (U50488)-receptors, and its reversibility by subcutaneously (s.c.) administered centrally penetrating antagonists beta-funaltrexamine (mu), naltrindole (delta) and nor-binaltorphimine (kappa), and by the peripherally restricted antagonist naloxone methiodide (NLXM). NLXM was also injected intracerebroventricularly (i.c.v.) before i.p. loperamide. Mu-, kappa- and, to a lesser degree, delta-receptors were expressed on peripheral nerve terminals in the peritoneum. The anatomical distribution of the opioid receptor staining was very similar to the staining for calcitonin gene-related peptide, a marker of sensory neurons. Morphine, U50488 and, to a lesser degree, SNC80 blocked acetic and acid induced writhes. These effects were reversed by beta-funaltrexamine, nor-binaltorphimine and naltrindole, respectively. NLXM (s.c.) reversed antinociceptive effects of morphine, SNC80 and U50488 by 57%, 80% and 47%, respectively. Loperamide (0.05 mg/kg)-induced antinociception was reversed by s.c. beta-funaltrexamine and NLXM. Loperamide (0.1 mg/kg)-induced antinociception was completely blocked by s.c. beta-funaltrexamine but was only attenuated (by 50%) by s.c. or i.c.v. NLXM. In conclusion, systemically administered centrally penetrating mu-, delta- and kappa-agonists produced a substantial part of antinociception through peripheral opioid receptors. Higher dose loperamide-induced antinociception involved also central opioid receptors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17599812     DOI: 10.1016/j.brainres.2007.05.049

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  41 in total

Review 1.  Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain.

Authors:  Bernard P Roques; Marie-Claude Fournié-Zaluski; Michel Wurm
Journal:  Nat Rev Drug Discov       Date:  2012-04       Impact factor: 84.694

Review 2.  Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Ther Deliv       Date:  2011-08

3.  Pain imaging in the emerging era of molecular medicine.

Authors:  Christian S Stohler; Jon-Kar Zubieta
Journal:  Methods Mol Biol       Date:  2010

4.  A pharmacokinetic and pharmacodynamic study of oral oxycodone in a human experimental pain model of hyperalgesia.

Authors:  Anne E Olesen; Richard Upton; David J R Foster; Camilla Staahl; Lona L Christrup; Lars Arendt-Nielsen; Asbjørn M Drewes
Journal:  Clin Pharmacokinet       Date:  2010-12       Impact factor: 6.447

Review 5.  Peripheral mechanisms of pain and analgesia.

Authors:  Christoph Stein; J David Clark; Uhtaek Oh; Michael R Vasko; George L Wilcox; Aaron C Overland; Todd W Vanderah; Robert H Spencer
Journal:  Brain Res Rev       Date:  2008-12-31

6.  The opioid antagonist, β-funaltrexamine, inhibits NF-κB signaling and chemokine expression in human astrocytes and in mice.

Authors:  Randall L Davis; Subhas Das; J Thomas Curtis; Craig W Stevens
Journal:  Eur J Pharmacol       Date:  2015-05-22       Impact factor: 4.432

Review 7.  Recent Advances in Peripheral Opioid Receptor Therapeutics.

Authors:  Raghav Seth; Sumanth S Kuppalli; Danielle Nadav; Grant Chen; Amitabh Gulati
Journal:  Curr Pain Headache Rep       Date:  2021-05-10

8.  Acetaminophen modulates P-glycoprotein functional expression at the blood-brain barrier by a constitutive androstane receptor-dependent mechanism.

Authors:  Lauren M Slosky; Brandon J Thompson; Lucy Sanchez-Covarrubias; Yifeng Zhang; Mei-Li Laracuente; Todd W Vanderah; Patrick T Ronaldson; Thomas P Davis
Journal:  Mol Pharmacol       Date:  2013-09-09       Impact factor: 4.436

9.  Functional selectivity of kappa opioid receptor agonists in peripheral sensory neurons.

Authors:  Raehannah J Jamshidi; Blaine A Jacobs; Laura C Sullivan; Teresa A Chavera; Rachel M Saylor; Thomas E Prisinzano; William P Clarke; Kelly A Berg
Journal:  J Pharmacol Exp Ther       Date:  2015-08-21       Impact factor: 4.030

10.  Β-funaltrexamine inhibits chemokine (CXCL10) expression in normal human astrocytes.

Authors:  Randall L Davis; Subhas Das; Daniel J Buck; Craig W Stevens
Journal:  Neurochem Int       Date:  2013-01-31       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.